- Home
- DXC vs GHRS Comparison
DXC vs GHRS Comparison
Compare DXC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | GHRS |
|---|---|---|
| Founded | 1959 | 2018 |
| Country | United States | Ireland |
| Employees | 115000 | 73 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXC | GHRS |
|---|---|---|
| Price | $10.80 | $28.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 3.7M | 322.3K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $12,644,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $11.83 |
| 52 Week High | $15.68 | $31.44 |
Technical Indicators
Market Signals| Indicator | DXC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 48.98 |
| Support Level | $7.92 | $28.05 |
| Resistance Level | $11.38 | $28.96 |
| Average True Range (ATR) | 0.47 | 1.50 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 37.75 | 11.46 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.